Aclidinium Bromide 相關新聞
Aclidinium Bromide 目前有 0 則相關新聞報導,預測適應症 20 個。
本頁整合 Aclidinium Bromide 的 AI 預測適應症與最新健康新聞,橘色標示的適應症表示近期有相關新聞報導。
藥物資訊
- 原適應症:Bretaris Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
- 證據等級:L5
- 預測適應症(20 個):
- open-angle glaucoma(89.4%)
- primary hereditary glaucoma(89.0%)
- migraine disorder(86.2%)
- migraine with brainstem aura(85.4%)
- irritable bowel syndrome(84.6%)
- headache disorder(83.5%)
- trigeminal autonomic cephalalgia(82.7%)
- glaucoma 1, open angle(79.6%)
- gastroduodenitis(79.5%)
- dermatitis(79.3%)
- obsolete rare pulmonary disease(79.1%)
- peptic ulcer disease(78.5%)
- dysthymic disorder(78.0%)
- acrodermatitis chronica atrophicans(77.6%)
- common cold(77.2%)
- neonatal dermatomyositis(76.6%)
- hydroa vacciniforme, familial(76.0%)
- atrophoderma vermiculata(75.6%)
- secondary interstitial lung disease specific to childhood associated with a connective tissue disease(75.6%)
- amyopathic dermatomyositis(75.3%)
相關新聞(0 則)
目前沒有相關新聞報導。當有新聞提到此藥物時,系統會自動收集並顯示在這裡。
免責聲明:本頁新聞由系統自動收集,僅供研究參考,不構成醫療建議。